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Abstract
Background: General practitioners (GPs) have gradually become more involved in the prevention of cardiovascular 
disease (CVD), both through more frequent prescribing of pharmaceuticals and by giving advice regarding lifestyle 
factors. Most general practitioners are now faced with decisions about pharmaceutical or non-pharmaceutical 
treatment for primary prevention every day. The aim of this study was to explore, structure and describe the views on 
primary prevention of cardiovascular disease in clinical practice among Swedish GPs.
Methods: Individual interviews were conducted with 21 GPs in southern Sweden. The interview transcripts were 
analysed using a qualitative approach, inspired by phenomenography.
Results: Two main categories of description emerged during the analysis. One was the degree of reliance on research 
data regarding the predictability of real risk and the opportunities for primary prevention of CVD. The other was the 
allocation of responsibility between the patient and the doctor. The GPs showed different views, from being convinced 
of an actual and predictable risk for the individual to strongly doubting it; from relying firmly on protection from 
disease by pharmaceutical treatment to strongly questioning its effectiveness in individual cases; and from reliance on 
prevention of disease by non-pharmaceutical interventions to a total lack of reliance on such measures.
Conclusions: The GPs' different views, regarding the rationale for and practical management of primary prevention of 
CVD, can be interpreted as a reflection of the complexity of patient counselling in primary prevention in clinical 
practice. The findings have implications for development and implementation of standard treatment guidelines, 
regarding long-time primary preventive treatment.
Background
During the past few decades, there has been a substantial
increase in prescribing of medicines for prevention of
cardiovascular disease (CVD) in Sweden as well as in
other countries [1,2]. The former reluctance to prescribe
for example lipid-modifying agents [3] seems to have
been overcome in Sweden, although internationally they
are still considered to be underused [4,5]. More and more
attention has also been paid to research on the influence
of lifestyle factors, such as smoking, stress, alcohol con-
sumption, exercise and food habits, on long-term cardio-
vascular health [6-8].
Most doctors in primary care are faced with decisions
about pharmaceutical or non-pharmaceutical treatment
for primary prevention everyday, i.e., decisions regarding
treatment of individuals with risk factors but without
manifest disease. There are ethical consequences
involved, since treatment may lead to perceptions of ill-
ness when the 'healthy' patient becomes medicalized
[9,10]. Information on indicators of risk for cardiovascu-
lar events, and the risks of lifestyle factors is frequently
featured in the mass media, and public awareness has
been considered high in Sweden [11]. During recent
years, different models have been introduced for calculat-
ing and scoring risk as aids to treatment decisions [12].
Risk interpretation and risk communication are impor-
tant topics for debate and research [13].
According to the Swedish definition of hypercholester-
olemia (>5 mmol/l serum), 90-95% of the population
between 50-70 years of age are hypercholesterolemic.
One quarter of the population, from 20 years of age, is
defined as hypertensive [6,14]. According to an analysis
from 2005, based on individual data from a new Swedish
health database, 53% of the Swedish population aged 60
years or more purchased prescribed preventive cardio-
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vascular drugs, such as antihypertensive or serum-lipid
reducing agents [15]. Guidelines have been changed from
time to time and when the standard levels are lowered, an
i n c r e a s i n g  f r a c t i o n  o f  t h e  p o p u l a t i o n  i s  l i k e l y  t o  b e
exposed to preventive actions, leading to more frequent
situations involving information and treatment decisions.
The primary level of health care in Sweden is organized
in health centres with specialists in general practice, here-
after called general practitioners (GPs). GPs have a key
role in drug prescribing and to provide information and
make decisions regarding preventive actions in relation to
cardiovascular disease. Previous studies have shown that
views on treatment options can differ greatly also within
a seemingly homogenous group such as Swedish GPs
[3,16]. Awareness of such differences in views may also
influence how guidelines are actually translated into clin-
ical practice and are therefore of interest for development
of treatment guidelines, as well as for GPs' reflections and
discussions in their everyday practice.
The aim of this study was to explore, structure and
describe the views on primary prevention of CVD and
the experiences in clinical practice among Swedish GPs.
Methods
In order to be able to explore views in an unlimited way, a
qualitative approach was applied. The analysis was
inspired by phenomenography, that aims to investigate
the different ways in which people understand a particu-
lar phenomenon and present the variation in the form of
categories of description [17,18].
Twenty-one GPs in Halland, a county in the South of
Sweden, were interviewed and the interviews were analy-
sed qualitatively to explore and structure the spectrum of
views on primary prevention of CVD. Purposive sam-
pling was used in order to ensure participation of GPs of
different age, gender, length of experience, type of health
centre (public or private) and recruitment area (urban or
rural). The twenty-one doctors, 13 male and 8 female
(Table 1), were recruited step-wise from a total of 50 GPs.
First, the GPs were contacted by a preparing letter and
asked to confirm their willingness to participate in the
study by e-mail or telephone. They were informed of the
voluntariness and they were also informed about their
right to anonymity. Those who did not respond the first
time were contacted again by e-mail or telephone. When
a GP denied participation, a GP with similar characteris-
tics was contacted. The most common obstacles to par-
ticipation were a heavy workload and lack of time. All
GPs included in the study were working in the same
county council area, using the same treatment guidelines.
All 21 GPs were interviewed by the first author (LS) and
all interviews were audio-tape recorded and lasted 30 to
60 minutes. They were conducted during the period
October 2004 to March 2005. Informed consent was
signed before the interviews started. Sixteen of the inter-
views were made face to face, and five were telephone
interviews. These five GPs declined participation in a
face-to-face interview, due to perceived lack of time, but
accepted a telephone interview. They were included as
they had unique combinations of characteristics (Table
1). The interviewees were encouraged to describe and
reflect upon examples from their own practice. The
emphasis was placed on the doctors' personal views and
experiences, and not on their knowledge or perceptions
of national or regional guidelines. The interviews were
semi-structured and followed an interview-guide with
suggested questions and probing areas (Table 2). Depend-
ing on the flow in the interview, and the expressiveness of
the interviewee, the interviewer asked the questions
more in general or in detail but aimed at having the main
topics covered. First the topic was introduced in a general
way, and if necessary, probing questions were asked to
ensure that the expressed views covered the topics.
The audio-tape recorded interviews were transcribed
verbatim by the first author (LS) and the transcripts were
checked by re-listening. All transcripts were read several
times and expressions related to the aim of the study were
marked in the texts. The first author (LS, a pharmacist)
conducted the initial analysis, while the two other authors
(RW, a specialist in family medicine, and CSL, a pharma-
cist), both with long experience of qualitative analysis of
interview material, participated as co-evaluators. To get
an overview, and facilitate the analysis, the marked
expressions were transferred to an Excel-file with one col-
umn for each of the 21 interviews. The expressed views
were coded and through further analysis of the meaning
Table 1: GP characteristics
Gender: Female 8
Male 13
Age: <50 years 8
>50 years 13
Education: Full, specialist 16
Specialist training 5
Native language: Swedish 17
Other 4
Type of Health centre: Public 16
Private 5
Patient recruitment 
area:
Urban 10
Rural 11Silwer  et al. BMC Family Practice 2010, 11:44
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of each coded expression, two main categories gradually
emerged. Expressions related to these were then divided
into separate files for further structuring, analysis and
description of the variation in views within the main cate-
gories and sub-categories. During the whole process, the
material was related to the full transcripts, not to lose the
original context. The authors carried out a continuously
cooperative analysis resulting in a structured presenta-
tion in main categories and sub-categories of the varia-
tion in views on primary prevention of CVD among GPs.
The study was approved by The Regional Ethical
Review Board in Göteborg, Sweden, registration number
241-04. Participation was voluntary and the participants
were informed that they could withdraw from the study
at any time. They were guaranteed confidentiality accord-
ing to existing rules.
Results
During the analysis of the interviews, two main catego-
ries of description emerged:
i) Degree of reliance, as a comprehensive term for
belief in research data regarding the predictability of
actual risk of cardiovascular disease, and regarding
the possibilities or ways to prevent disease by primary
prevention;
ii) Allocation of responsibility, regarding different
aspects of primary prevention.
For each of these main categories, the variations in
views in the different sub-categories are presented in the
text, and summarised in table 3. A distinctive variation
was found in the ways GPs experienced management of
people with cardiovascular risk factors and in their beliefs
in primary prevention of CVD. Some had, according to
their own statements, changed from emphasizing phar-
maceutical treatment to non-pharmaceutical measures
(here defined as miscellaneous lifestyle changes), while
others had changed in the opposite direction during the
same period of time. No obvious pattern of linked views
was found, but rather different combinations of indepen-
dent views. Some doctors shared their experiences of the
complexity regarding both reliance and responsibility.
"In one way we medicalize an unhealthy lifestyle, we
give medicines as a substitute for people taking care of
themselves... but it is not that simple either to do with-
out (medicines), because if you do, things can hap-
pen..." (GP18)
"I control the information, the prescribing decision is
shared, but whether or not they then purchase and
take the medicines, I don't control that..." (GP16)
Reliance
There were some recurrent topics regarding reliance,
where quite uniform views were expressed: that it is often
inappropriate or too difficult to present the patient with a
numerical estimate of risk or risk score; that it is more
important to treat hypertension than hyperlipidaemia
pharmaceutically; that lifestyle intervention, such as
smoking cessation, is more important for younger people;
Table 2: Interview guide
Main topics Probing questions
Communication of risk and risk 
reduction
How do you usually communicate/inform the patient of the results of the tests and of risk - 
numerically, graphically or how? How do you explain what it means?
Most important to be said?
"Typical" patient reaction?
Numerical or non-numerical presentation of benefits and risks? Always talk about non-pharmaceutical 
treatment?
Risk for you not to prescribe - in hypertension/in hyperlipidemia?
Talk about follow-up, treatment targets, treatment length and possible adverse effects?
Treatment decision How is the treatment decision made - what is the role of the patient? What would the optimal situation 
be?
How often pharmaceuticals immediately?
Difference in handling of hyperlipidemia and hypertension? Difference in handling of patients of 
different ages?
Other aspects of primary prevention Has there been any shift in your view of primary prevention in later years - why?
What is the most difficult about primary prevention of CVD?
How would you treat yourself and your personal risk factors?
Is there anything you would like to add regarding primary prevention?S
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Table 3: Summary table
RELIANCE Fields of agreement
Too difficult and inappropriate to give the patient a numerical estimate of cardiovascular risk or risk score; more important to treat hypertension than hyperlipidaemia 
pharmaceutically; lifestyle intervention is more important for younger people; reduced drug prices influence prescribing criteria; individualization of advice and treatment 
is necessary; testing and prescribing drugs without proper indication can make patients feel ill
Fields of variation
1. Trust in pharmaceutical prevention A. Firm trust in effectiveness and cost-effectiveness of pharmaceutical prevention
B. Some doubts about the effectiveness for the individual patient
C. Expressed doubts due to insufficient evidence
2. Trust in non-pharmaceutical 
prevention
A. Non-pharmaceutical treatment is the basis
B. Non-pharmaceutical treatment is too difficult to carry out and not very effective
C. Non-pharmaceutical treatment is not effective and it impairs the quality of life for the patients
3. Importance of a treatment goal A. A pre-defined target is necessary
B. The importance of a target is varying: important for high-risk patients but not for low-risk patients
C. The lowering of blood-pressure or lipids is the most important, not to a certain value
4. Pharmaceutical prevention for 
different ages
A. More important for younger individuals
B. Equally important for young and old
C. More important for older individuals
RESPONSIBILITY Fields of agreement
Genetic disposition is a significant risk factor; the "western" lifestyle causes cardiovascular disease; smoking is the most important lifestyle risk factor; a positive expectation 
that the intervention is beneficial is a necessary condition for compliance
Fields of variation
1. Information regarding potential 
adverse effects and length of 
treatment
A. Important to inform for the patient to be prepared and feel safe
B. Avoiding information is better, not to worry the patient
2. Treatment decision A. The doctor has the main responsibilityS
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B. A decision on equal terms is preferred
C. The patient has the main responsibility
3. The role of the doctor in non-
pharmaceutical treatment
A. The doctor's role is to confront the patient with uncomfortable recommendations and make demands on the patient
B. The doctor's role is to communicate a positive message and encourage every little step the patient takes towards a healthier 
lifestyle
C. It is too difficult for the doctor to talk about lifestyle risk factors without blaming or burdening the patient. The doctor has no 
important role in non-pharmaceutical treatment
D. The doctor has no right to demand a change in the patient's lifestyle, but should instead prescribe pharmaceuticals for smokers 
and over-weight people
Table 3: Summary table (Continued)Silwer  et al. BMC Family Practice 2010, 11:44
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that it is necessary to individualize the advice and treat-
ment given; and that there is a risk of making patients feel
ill by ordering tests without a proper indication, and by
prescribing drugs.
The belief in an actual predictable risk for the individ-
ual, and the reliance in effectiveness of primary preven-
tion of CVD varied, which will be described in the
following four sub-categories with the internal variation
illustrated by expressions:
1) Practical experience of actual risk of CVD, and trust
in pharmaceutical prevention of CVD by lipid-lowering
or antihypertensive treatment:
A: Firm trust in the scientific documentation of effec-
tiveness for the individual and of cut-off points as true
levels of increased predictable risk. Pharmaceutical
treatment is cost-effective and saves money by reduc-
ing the number of myocardial infarctions and stroke,
and thereby the related intensive care.
"... it must be the medicines that did it, mustn't it, it
saved lots of money, I think, it's costly intensive care,
MI and stroke and those things" (GP 2)
B: Some doubts about the effectiveness for the indi-
vidual, but acceptance of the guidelines as rules to
obey (even if they change over time), hoping and
wishing that one is doing the best for the patient. Pri-
mary prevention was considered time-consuming and
more difficult than secondary prevention, as the evi-
dence in its favour is not unambiguous.
"How much should you treat people who feel well and
are healthy, so to speak, and who have risk factors, I
don't think that is completely obvious, it is not, and it
would be a bit heavy if too much of your time would be
consumed by treating prospective risks... In a way it's
easier when there is a disease and you know that you
are doing more good. (GP 7)
C: Expressed doubts, due to the meagre evidence for
long-term treatment, both in terms of beneficial and
adverse effects. The pharmaceutical industry puts
pressure on the prescribers. The benefit for the indi-
vidual was considered to be marginal and the doctor's
duty is among other things to tone down the risks and
relate them to other risks in life.
"...but there is a pharmaceutical industry that puts
pressure on us, it's in newspapers etc, we are continu-
ally fed with this... and I think it is as much my duty to
sit here and tone down the risks for the young ones,
above all. It doesn't seem reasonable that the majority
of the population should take medicines" (GP 10).
2) Trust in non-pharmaceutical prevention:
A: Non-pharmaceutical treatment is the basis, with
the greatest chances and the least adverse effects,
while pharmaceutical treatment is a supplement. The
project "Physical activity on prescription" [19] was
mentioned as a positive example.
"And the lifestyle is like the main thread in the whole
treatment, getting tablets doesn't mean that you don't
have to change your lifestyle" (GP 13).
B: Doubts about the effectiveness of non-pharmaceu-
tical treatment as it is difficult to carry out. Most
patients are elderly and for them it is even harder to
be physically active or to change their eating habits in
a radical way and then it is better to prescribe phar-
maceuticals.
"Because most patients you see in real life are elderly,
and there you only find high levels, and you realise
that you can give this advice about their lifestyle, but
they will not be very effective on this person so you'd
better prescribe pharmaceuticals" (GP 1)
C: Non-pharmaceutical treatment is not effective and
it is important, in primary prevention, to avoid nega-
tive impacts on quality of life through changes in life-
style, since we are mostly dealing with people who feel
healthy before they get treatment.
"...and I must say that sometimes I imagine myself in
the choice between changing my eating habits... and
remembering and thinking a lot about what I eat...
and taking a tablet ... I would prefer taking a tablet
and go on living as usual..." (GP 9)
3) Aiming at a numerical value of treatment target or
not (for blood pressure and blood lipids):
A: Awareness of a target for the treatment is a neces-
sary condition to enable the patient to see that the
treatment is effective.
"...We define what we aim at when we start the treat-
ment. The patient should always know what target he
or she should reach" (GP 13).
B: The importance of a numerical treatment target
varies in each specific case. For high-risk patients,
defined goals are important, but for low-risk patients
they are not. For some GPs, the importance of a
defined target was mainly related to hypertension, but
regarding hyperlipidemia it was not considered so
important.
"...if there is a high risk, you set clear goals, if there is a
fairly low risk, I don't talk very much about it but start
treatment ...I think you have more defined goals when
you treat blood pressure..." (GP 9).
C: Lowering the blood pressure or blood lipids in gen-
eral is the most important thing, rather than aiming
for a certain value, as long as the evidence is too poor
to clearly define treatment targets.
"...and I think it is reasonable that as long as we do not
know, we should not just look at target values" [regard-
ing lipid-lowering] (GP 15).
4) Consequences of age regarding pharmaceutical
treatment (younger = 40 years; older = 70 years):
A: It is more important to treat younger people, as
they are likely to have more years to live.Silwer  et al. BMC Family Practice 2010, 11:44
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"Yes, you drill the 40 year-old much more. But the 70
year-old will comply better... yes, you have a com-
pletely different ambition for the 40 year-old... and you
start pharmaceutical treatment faster on the 40 year-
old" (GP 18).
B: It is equally important to treat younger and older
people, while on the one hand a cardiovascular event
is more likely during the next 20 years for the older
person, and on the other hand, the probability of get-
ting CVD before arriving at a very old age is greater
for the younger one.
"Looking at the arguments from two different positions
you might consider it important in both cases" (GP 19)
C: Treating older people is more important, because
knowledge is lacking about the effectiveness of start-
ing a treatment at a young age which is intended to
continue for 30-40 years.
"...the risk during the following years is much higher if
you are older... and most of what we know about is just
how to prevent events during the first few years ahead.
How much you prevent atherosclerosis by treating a 25
year-old, to prevent a possible infarction at the age of
50 or 60... we know very little about that ... it takes
higher levels for younger than for older people" (GP 9)
Responsibility
The significance of genetic disposition as a risk factor was
frequently emphasized, and regarding the responsibility
for avoidable risk factors, the "western" life style was uni-
formly seen as a cause of cardiovascular disease, both at
population level and individual level. Smoking was seen
as the most important lifestyle risk factor. A quite general
view was also found regarding responsibility for compli-
ance and outcome of pharmaceutical treatment. A firm
conviction, that the intervention is beneficial, was consid-
ered a fundamental prerequisite for patients being able to
take their medicine regularly, even if they feel healthy.
Here, the doctor's persuasive attitude towards the patient,
creating a positive expectation, was considered impor-
tant.
However, in three sub-categories there was a variation
in views on responsibility regarding different aspects of
primary prevention:
1) Information of potential adverse effects of pharma-
ceuticals and the likely length of treatment:
A: It is important to inform about potential adverse
effects of pharmaceuticals or probable length of treat-
ment from the beginning, for the patient to be pre-
pared and feel safe.
"I always inform the patient about adverse effects ini-
tially and then they report if they get any" (GP 13).
B: It is better to avoid informing the patient about
adverse effects or the length of the treatment at the
outset, in order not to worry the patient.
"You never talk about the eventuality of life-long treat-
ment, never during the first meeting... I think that is
like shoving it down their throats when they feel quite
weak already... that's bad timing" (GP11).
2) Shared responsibility (doctor and patient) for the
treatment decision:
A: The doctor has the main responsibility, because he
or she has the adequate skills and enjoys the patient's
confidence to make the decisions, and because the
patients sometimes make themselves dependent and
are unwilling to decide.
"...I don't understand how they could possibly make
their own assessment - in most cases they don't have
any basis for assessment or decision for that, so to
speak" (GP 3)
B: A decision on equal terms is preferred, as the doc-
tor has knowledge about the disease and the patient
about his or her personal situation. The discussion
between the two of them is important, and they usu-
ally arrive at an agreement.
"...yes it's on equal terms, I have the knowledge of the
disease and the patient of himself or herself and their
personal situation, and we try to reach a good conclu-
sion from that" (GP 20)
C: The patient has the main responsibility, and this is
a prerequisite for compliance. This category also
includes the views that in order to motivate the
patient, the doctor could inform (or persuade) the
patient, but the decision is the patient's alone.
"...When I feel that they have understood, I can relax,
whereas they can make the decisions regarding their
own lives" (GP 9)
3) The doctor's role and responsibility in non-pharma-
ceutical treatment:
A: The doctor's role is to confront the patient with
uncomfortable recommendations regarding the
patient's own responsibilities, as it is necessary for a
successful pharmaceutical treatment to demand that
the patient carries out non-pharmaceutical activities.
"If they smoke a lot, I usually tell them that it would be
ridiculous to treat your blood pressure and your cho-
lesterol if you keep on smoking. There is no point in
doing that. I am usually quite mean then" (GP 4)
B: The doctor's role is to communicate a positive mes-
sage about what one can do oneself, in conjunction
with the primary diagnosis of an elevated blood pres-
sure or lipid level. This role is also important in mak-
ing the patient ponder over what they might do
themselves and what interventions might be realistic
in their situation, and further, in encouraging every
little step the patient takes towards a healthier life-
style.
"You want somehow to give them something positive to
cling to... that if I can do this and that and I can stopSilwer  et al. BMC Family Practice 2010, 11:44
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smoking or I can go down in weight or if I can be a little
more physically active, I will have lots to gain" (GP 1).
C: It is difficult to talk about the risk factors in the
patients' lifestyle, without blaming or burdening
them. The doctor's role in lifestyle change is insignifi-
cant and the roles of nurses and dieticians are more
suited for such communication in health information
talks and follow-ups, but there are too few dieticians.
"As a doctor you can do very little to help directly
regarding overweight... and furthermore it's a topic
covered with shame..." (GP 9)
D: The doctor has no right to demand a change in the
patient's lifestyle which makes pharmaceutical treat-
ment even more important to smokers and over-
weight people.
"I don't consider myself having the right to demand
that people stop smoking. I think it is presumptuous to
make such strong demands." (GP 11)
Discussion
The views on different aspects of primary prevention var-
ied, despite the fact that all the GPs in our study worked
in the same county and were recommended to use the
same guidelines which theoretically could have restricted
the variation. There could have been a risk that GPs that
were especially interested in pharmaceutical treatments
or up-to-date regarding guidelines would be more willing
to participate in the study and share their time to discuss
these subjects, but such a selection is unlikely as a wide
variation in views was found. The combination of partici-
pants in the study, together with the fact that the local
guidelines were very similar to the national guidelines
and also to the European guidelines, could be considered
a ground for transferability of the results, as these local
experiences might be assumed to be universal and to
reflect those of GPs in other parts of the country, and
probably also in other countries.
By asking the GPs to present their own descriptions of
managing cases of primary prevention, material that was
close to their actual practice was received and could
thereby be considered as reflecting their genuine views.
The credibility of this study is also strengthened by the
fact that all interviews were performed by one inter-
viewer, although the fact that the interviewer was known
to be a pharmacist, at the time employed by the National
Corporation of Pharmacies in Sweden, might have
affected the dialogue on pharmaceutical treatment to
some extent. Five of the interviews were made by tele-
phone, to save time and enable selected GPs to partici-
pate. These interviews were however as comprehensive
as the face-to face interviews and were therefore included
in the material.
The credibility of the analysis of the study is enhanced
by the way the three authors' analysed and continuously
discussed the interview material. Two of the authors have
long experience in analysing this type of qualitative mate-
rial, in particular interviews with doctors [3,16].
The two main categories, degree of reliance and alloca-
tion of responsibility, were interlaced, with responsibility
appearing as a consequence of reliance in terms of oppor-
tunities to prevent disease. The view of cardiovascular
risk, as an actual risk for the individual, could be seen as a
central condition for the belief in a capability to reduce
risk in any way. Using numerical risk or numerical risk
reduction, in communication with the patient, was
mostly considered inappropriate or too difficult.
Some GPs in our study felt a great responsibility to treat
the patient in an optimal way, pharmaceutically or non-
pharmaceutically, based on their knowledge of research
d a t a  o n  n u m e r i c a l l y  r e d u c e d  r i s k .  T h e y  w e r e  a n x i o u s
about not doing well enough as if they were in a way hav-
ing the patients' lives in their hands, already in the case of
primary prevention. Others considered that in order to
act beneficially towards the patient, their informative role
and responsibility was to relate the magnitude of CVD
risk to other risks in the patients' lives. Good risk com-
munication is often considered a prerequisite for patient
involvement in treatment decisions and GPs are sup-
posed to have an important role in communicating the
meaning of risk [13]. A tendency to overestimate absolute
cardiovascular risk has been reported for both physicians
and patients [13] and in other studies the physicians were
found to usually tell the patient that an adverse outcome
was certain, unless the patient adopted the recommended
treatment [20,21]. It has also been stated that patients
were less likely to take antihypertensive drugs if they had
accurate information about their levels of risk [22]. An
interpretation could be that compliance by asymptomatic
individuals, to take pharmaceuticals regularly for
decades, is correlated to fear of disease or death. The risk
of making healthy individuals feel ill through primary
prevention, as expressed by some GPs in our study, there-
fore seems impossible to avoid.
Although the respondents uniformly put forward
genetic disposition as the background for disease, they
also expressed thoughts about the individual's responsi-
bility for risk factors. Some of the GPs thought that phar-
maceutical treatment was considered more important to
smoking and overweight individuals, as they felt that the
doctor has no right to demand a change in the patient's
li f es t yl e.  Also  in so m e o t he r  st u dies,  t he  f ea r of  m o ra l
intrusion or placing guilt on the patient has been
expressed [23,24]. Preventive thinking has been said to be
founded in part on perceptions of causal connections that
assign responsibility to the individual [9], but it has also
been stated that great confidence in modern medical sci-
ence, could impede changes in life style [25].Silwer  et al. BMC Family Practice 2010, 11:44
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We found contradicting views regarding the reliance on
research data in relation to the effectiveness of preven-
tion. The ideas expressed in the sub-categories varied
crosswise in different dimensions and did not appear as
linked, since for example reliance on effectiveness of
pharmaceutical prevention did not exclude reliance on
the effectiveness of non-pharmaceutical prevention. In a
British interview study from 1994, many findings were
similar to ours: that the profession creates fear and a
creeping medicalization in the population, that the lack of
evidence for risk identification and interventions is prob-
lematic, and that interpretation of probabilistic epidemi-
ological data is difficult in the individual case [23]. Also in
an American survey of practising family physicians,
regarding treatment of hyperlipidemia, a large variability
in beliefs and practice patterns was found [26].
Participants in our study expressed the view that the
role of the physician is different in primary and secondary
prevention. In a Scottish qualitative study from 1998, GPs
were reported to be less clear about the evidence for sta-
tins in primary prevention than in secondary prevention,
and found social and economic issues more complex
regarding primary prevention [27]. The results of another
qualitative British interview study from 2003 showed that
the GPs experienced difficulties in interpreting primary
prevention risk assessment tools, and they also had con-
cerns about increased workload and medicalization [28].
In a French qualitative interview study, patients and phy-
sicians agreed on the difficulties associated with imple-
menting lifestyle changes and adhering to long-term
treatment [29].
The GPs in our study had various views on the role of
the patient in the treatment decision, and they also
expressed different views about the responsibility of the
physician for the outcome of the drug treatment or the
lifestyle intervention. In terms of treatment decisions,
similar variations in views among physicians about
patient participation were found in another study of
Swedish GPs [16]. Other studies also report that time
constraints inhibit information provision, and that there
c o u l d  b e  a  r i s k  t h a t  e n c o u r a g i n g  p a t i e n t s  t o  c h o o s e
between competing treatment options would place an
additional burden on the patients, and lead to unneces-
sary anxiety and stress [23,24]. When patients are
involved in treatment decisions, they have to realise the
possible harms and benefits of the choices they face [30].
It has been stated in the literature, that preventive work is
rendered even more difficult when combined with pro-
fessional uncertainty, as in the case of pharmaceutical
primary prevention [21]. In an interview study with Dan-
ish GPs, about their feelings of discomfort or pleasure
regarding prescribing different groups of medicines, sta-
tins were mainly graded at the side of discomfort [31].
Preventive treatments, and the sick role thereby imposed
on a great number of people, were among the most diffi-
cult areas and were put forward as problematic fields
regarding Danish GPs' autonomy and self-perception
[31,32].
The interviews were performed during the years 2004
to 2005, and guidelines regarding cardiovascular preven-
tion have been revised since then - the national guidelines
in 2006 and the European guidelines in 2007 [33,34].
However, it is unlikely that these new guidelines,
although well developed, would change the deeper per-
sonal views and beliefs to any substantial extent. The
summary of the ESC (European Society of Cardiology)
guidelines also emphasizes, among other things, that
"The preventive interventions must be based on a
patient-centred approach, where the doctor pays full
attention to appraise and meet the patient's concerns,
beliefs, and values, and respects the patient's choice even
if it is not in concordance with the doctor's first proposal.
To change lifestyle or take medication often means for
the rest of the patient's life, so the decision must be
owned by the patient" [34]. Balancing the patient's beliefs
and values, the national or international guidelines and
the doctor's beliefs and values will still be a daily task for a
GP. Our findings further emphasize the necessity of a
continuous discussion among GPs, regarding managing
primary prevention in clinical practice.
Conclusions
Despite uniform guidelines, the views and beliefs about
the beneficial effects of primary prevention of CVD var-
ied considerably among the GPs, which might be inter-
preted as a reflection of the complexity of patient
counselling in this field. The findings should be used to
stimulate discussions regarding primary prevention of
CVD among GPs, and could also add information when
developing modified treatment guidelines, regarding
long-term primary preventive treatment, and when plan-
ning for the implementation of such guidelines.
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